Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of access for kidney transplant patients to (a) Evusheld and (b) other drugs that help increase resistance to covid-19.

Kidney transplant patients are eligible for community-based treatments via COVID Medicines Deliveries Units, which includes antiviral and neutralising monoclonal antibody treatments.

While Evusheld had been granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency on 17 March 2022, it highlighted uncertainty on the appropriate dose needed for protection against the Omicron variant. The UK Health Security Agency is undertaking further testing which will inform any decisions on next steps, including procurement.